Oppenheimer believes that the recent weakness in PTC has created a buying opportunity ahead of data on the company's P3 treatment due out in Q4. The firm says that even if the trial misses expectations, the drug could still generate sales that would make the stock's value $36 per share. Additionally, the firm believes that positive secondary data could support strong sales of the drug even if the primary data point misses. The firm recommends buying the stock below its $155 price target if the results are positive. It keeps an Outperform rating on the shares.